Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide + gefitinib versus gefitinib alone as first-line treatment for EGFR-mutant advanced lung adenocarcinoma
ChiCTR1800015212Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide and gefitinib in Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate and Progression-free survival. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
thalidomidegefitinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800015212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015212.